Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.61 |
| ▸ | HTR1A | P08908 | 4/20 | 0.53 |
| ▸ | DRD3 | P35462 | 2/20 | 0.53 |
| ▸ | HTR7 | P34969 | 1/20 | 0.53 |
| ▸ | HRH1 | P35367 | 1/20 | 0.53 |
| ▸ | HTR2B | P41595 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6710692 | 0.89 | DRD2 (0.49) | DRD2SLC6A4HTR1ADRD3HTR7 | |
| SCHEMBL6728261 | 0.86 | DRD2 (0.53) | DRD2SLC6A4HTR1ADRD3HTR7 | |
| SCHEMBL6784585 | 0.82 | DRD2 (0.49) | DRD2SLC6A4HTR1ADRD3HTR7 | |
| SCHEMBL6784237 | 0.81 | DRD2 (0.43) | DRD2SLC6A4HTR1ADRD3HTR7 | |
| SCHEMBL11809920 | 0.81 | DRD2 (0.53) | DRD2HTR1ADRD3HTR7 | |
| SCHEMBL6710735 | 0.81 | SLC6A4 (0.68) | DRD2SLC6A4ADRA1D | |
| SCHEMBL5937247 | 0.80 | ADRA1D (0.52) | DRD2HTR1ADRD3HTR7HRH1 | |
| SCHEMBL5730515 | 0.80 | ADRA1D (0.69) | DRD2SLC6A4HTR1AHTR7ADRA1D | |
| SCHEMBL6707980 | 0.80 | DRD2 (0.56) | DRD2HTR1ADRD3HTR7HRH1 | |
| SCHEMBL6707211 | 0.80 | DRD2 (0.63) | DRD2SLC6A4HTR1ADRD3HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077654-A1 | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | SMITHKLINE BEECHAM CORPORATION | 2004-04-22 | — | — | US | disclosed |
| EP-1351936-A1 | ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002055496-A1 | ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077654-A1 | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | LDLR, NR1H2, NCOR1 | DRD2 1008/4885SLC6A4 2034/4885HTR1A 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.